ProCE Banner Activity

CME

Expert Insight and Practical Guidance on Microsatellite Instability in Gastrointestinal Cancers

Review expert recommendations and key evidence for the use of immune checkpoint inhibitors in MSI-H gastrointestinal cancers in an expert panel discussion led by John L. Marshall, MD, along with Tim F. Greten, MD, and Yelena Y. Janjigian, MD. This program is divided into 4 segments. After clicking the Launch buttons below, the player will open in a new window. If it does not appear, please disable your pop-up blocker and try again. After reviewing all segments, click the Claim Credit button to the right to complete the CME posttest and evaluation.

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: December 22, 2017

Expiration: December 21, 2018

No longer available for credit.

Share

Faculty

John P. Leonard

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

Tim F. Greten

Tim F. Greten, MD

National Cancer Institute
Bethesda, Maryland
Former Associate Professor of Medicine
Department of Gastroenterology and Hepatology
Hannover Medical School
Hannover, Germany

Yelena Y. Janjigian

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Target Audience

This program is intended for oncologists, surgeons, pathologists, and other healthcare providers who care for patients with gastrointestinal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal therapies for patients with MSI-H gastrointestinal cancers and be prepared to integrate newer therapies as they emerge
  • Screen patients with gastrointestinal cancers for mismatch repair deficiencies, including microsatellite instability

Program Director Disclosure

Program Director

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

John L. Marshall, MD has disclosed that he has received consulting fees and funds for research from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho.

Faculty Disclosure

Primary Author

Tim F. Greten, MD

National Cancer Institute
Bethesda, Maryland
Former Associate Professor of Medicine
Department of Gastroenterology and Hepatology
Hannover Medical School
Hannover, Germany

Tim F. Greten, MD, has no real or apparent conflicts of interest to report.

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Yelena Y. Janjigian, MD, has disclosed that she has received funds for research support from Bayer, Bristol-Myers Squibb, Lilly, BI, Amgen, Roche, and Genentech and consulting fees from Lilly and Pfizer.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 22, 2017, through December 21, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to impart participant competence to encourage appropriate testing for MSI and utilization of MSI test results to guide the clinical care of patients with gastrointestinal cancers.